Angiopeptin inhibits intimal hyperplasia after angioplasty in porcine coronary arteries.
BACKGROUND
Restenosis is mediated by uncontrolled neointimal growth at the site of coronary angioplasty. Angiopeptin is an octapeptide analogue of somatostatin that has been shown to decrease the experimental intimal hyperplasia associated with vascular injury in rats and rabbits. The study purpose was to determine if angiopeptin inhibits the development of intimal hyperplasia in normolipemic swine coronary arteries after overstretch-balloon injury.


RESULTS
Overstretch-balloon injury was performed in normolipemic swine coronary arteries using a 3.5-mm angioplasty balloon. Treated animals received angiopeptin (50 micrograms/kg) 1 hour before and at the time of balloon injury. Angiopeptin was administered at 100 (micrograms/kg)/day SQ in two divided doses for 14 days. Animals were killed at 14 and 28 days (2 weeks after cessation of angiopeptin) after balloon injury. Treatment animals were compared with control animals receiving balloon injury alone. Angiopeptin significantly limited the experimental intimal hyperplasia estimated by the maximal intimal thickness and residual lumen (lumen area/lumen area+intimal area) compared with controls.


CONCLUSIONS
Angiopeptin inhibits the development of intimal hyperplasia in swine coronary arteries after balloon injury. The beneficial effect was detectable 2 weeks after cessation of angiopeptin therapy.
Santoian
E D
ED
Andreas Gruentzig Cardiovascular Center Department of Medicine (Division of Cardiology), Emory University School of Medicine, Atlanta, Ga.
Schneider
J E
JE
Gravanis
M B
MB
Foegh
M
M
Tarazona
N
N
Cipolla
G D
GD
King
S B
SB
D015906:Angioplasty, Balloon, Coronary; D000818:Animals; D003251:Constriction, Pathologic / Q000473:pathology / Q000517:prevention & control; D003331:Coronary Vessels / Q000293:injuries* / Q000473:pathology; D005260:Female; D006965:Hyperplasia; D009842:Oligopeptides / Q000008:administration & dosage / Q000627:therapeutic use*; D010456:Peptides, Cyclic; D012008:Recurrence; D013004:Somatostatin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013552:Swine; D013997:Time Factors; D017539:Tunica Intima / Q000187:drug effects* / Q000473:pathology
D009842:Oligopeptides; D010456:Peptides, Cyclic; C060347:lanreotide; D013004:Somatostatin